120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
帕金森病纳米治疗干预：调节致病机制并克服治疗障碍
Authors Yin X, Wang C, Lin W, Huang S, Chen T
Received 26 September 2025
Accepted for publication 22 January 2026
Published 7 February 2026 Volume 2026:21 570452
DOI https://doi.org/10.2147/IJN.S570452
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Eng San Thian
Xuanying Yin,* Chen Wang,* Weisen Lin,* Shuiqing Huang, Tongkai Chen
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tongkai Chen, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou, 510405, People’s Republic of China, Email chentongkai@gzucm.edu.cn
Abstract: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder globally. Despite significant research, effective clinical treatments for PD remain limited due to its complex pathogenesis and the selective nature of PD-related lesions. Advances in nanotechnology, however, have opened new avenues for PD therapy. Nanomedicines and nanomaterials, developed through interdisciplinary research, have shown the potential to enable precise and targeted drug delivery while modulating key pathogenic mechanisms involved in PD. This review first outlines the key pathophysiological mechanisms underlying PD before providing an overview of nanomedicine-based strategies designed to target PD lesions by altering these mechanisms. We also summarize clinical trials on emerging PD therapeutics, with particular focus on the development and translational potential of nanomedicines. Although nanotechnology-based treatments for PD are still in their infancy, and a definitive cure remains out of reach, this field shows considerable promise. Finally, we explore future prospects to guide the continued development of PD nanotherapies. Overall, this review highlights the transformative potential of nanomedicine in the treatment of PD and underscores its potential for the development of more effective and targeted PD therapies.
Keywords: Parkinson’s disease, nanomedicines, pyroptosis, ferroptosis, autophagy
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tongkai Chen, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou, 510405, People’s Republic of China, Email chentongkai@gzucm.edu.cn
Abstract: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder globally. Despite significant research, effective clinical treatments for PD remain limited due to its complex pathogenesis and the selective nature of PD-related lesions. Advances in nanotechnology, however, have opened new avenues for PD therapy. Nanomedicines and nanomaterials, developed through interdisciplinary research, have shown the potential to enable precise and targeted drug delivery while modulating key pathogenic mechanisms involved in PD. This review first outlines the key pathophysiological mechanisms underlying PD before providing an overview of nanomedicine-based strategies designed to target PD lesions by altering these mechanisms. We also summarize clinical trials on emerging PD therapeutics, with particular focus on the development and translational potential of nanomedicines. Although nanotechnology-based treatments for PD are still in their infancy, and a definitive cure remains out of reach, this field shows considerable promise. Finally, we explore future prospects to guide the continued development of PD nanotherapies. Overall, this review highlights the transformative potential of nanomedicine in the treatment of PD and underscores its potential for the development of more effective and targeted PD therapies.
Keywords: Parkinson’s disease, nanomedicines, pyroptosis, ferroptosis, autophagy